GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy plus chemotherapy before surgery shows promise against tough stomach cancers
Disease control Recruiting nowThis trial investigates whether adding the immunotherapy drug serplulimab (HLX10) to standard chemotherapy (S-1 and oxaliplatin) before and after surgery can improve outcomes for people with locally advanced, PD-L1-positive stomach or gastroesophageal junction cancer. Participant…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New Immune-Targeting drug could boost stomach cancer treatment
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug ASP2138 to standard chemotherapy and immunotherapy (pembrolizumab) helps people with a specific type of advanced stomach or gastroesophageal junction cancer live longer without their disease worsening. The study enroll…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug targets stomach and pancreatic cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called ASP2138, which helps the immune system attack cancer cells that have a specific marker (CLDN18.2). It is for people with advanced stomach, gastroesophageal junction (GEJ), or pancreatic cancer that cannot be removed by surgery or has…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for stomach cancer: experimental drug BHB810 enters human trials
Disease control Recruiting nowThis study tests a new drug, BHB810, in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety and find the best dose, while also seein…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: BigHat Biosciences, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill targets hard-to-treat cancers with specific gene flaw
Disease control Recruiting nowThis study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC